AstraZeneca says Baxdrostat reduces 24-hour systolic blood pressure
(Alliance News) - AstraZeneca PLC on Sunday announced results from the phase 3 trial of its Baxdrostat treatment which showed a statistically significant reduction in the systolic blood pressure of patients with resistant hypertension. Read More